MDS Inc. plans to broaden its position in life sciences research through a $615 million all-cash acquisition of Molecular Devices Corp. (BioWorld Today)
MDS Inc. plans to broaden its position in life sciences research through a $615 million all-cash acquisition of Molecular Devices Corp. (BioWorld Today)
PharmAthene Inc. is gaining a public listing and up to $70 million in cash through a planned merger with Healthcare Acquisition Corp., a deal coming months after another proposed merged by PharmAthene fell through. (BioWorld Today)
